How to buy Cidara Therapeutics stock (CDTX)

Cidara Therapeutics is a biotechnology business based in the US. Cidara Therapeutics shares (CDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23.69 – an increase of 2.02% over the previous week. Cidara Therapeutics employs 69 staff and has a trailing 12-month revenue of around $53.9 million.

Our top picks for where to buy Cidara Therapeutics stock

Buy Cidara Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cidara Therapeutics stock price (NASDAQ: CDTX)

Use our graph to track the performance of CDTX stocks over time.

Cidara Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$23.69
52-week range	$10.00 - $24.99
50-day moving average more info button	$16.68
200-day moving average more info button	$13.82
Wall St. target price	$29.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-23.90

Is it a good time to buy Cidara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cidara Therapeutics price performance over time

Historical closes compared with the close of $23.22 from 2024-12-26

1 week (2024-12-20)	23.22
1 month (2024-11-27)	14.95%
3 months (2024-09-27)	116.20%
6 months (2024-06-28)	94.47%

1 year (2023-12-28)	2,766.67%
2 years (2022-12-28)	83.96%
3 years (2021-12-28)	24
5 years (2019-12-27)	63.2

Cidara Therapeutics financials

Revenue TTM	$53.9 million
Gross profit TTM	$-11,232,000
Return on assets TTM	-15.66%
Return on equity TTM	-153.39%
Profit margin	-211.35%
Book value	$-1.81
Market Capitalization more info button	$256.3 million

TTM: trailing 12 months

Cidara Therapeutics share dividends

We're not expecting Cidara Therapeutics to pay a dividend over the next 12 months.

Have Cidara Therapeutics's shares ever split?

Cidara Therapeutics's shares were split on a 1:20 basis on 23 April 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cidara Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cidara Therapeutics shares which in turn could have impacted Cidara Therapeutics's share price.

Cidara Therapeutics share price volatility

Over the last 12 months, Cidara Therapeutics's shares have ranged in value from as little as $10.004 up to $24.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cidara Therapeutics's is 0.994. This would suggest that Cidara Therapeutics's shares are less volatile than average (for this exchange).

Cidara Therapeutics overview

Cidara Therapeutics, Inc. , a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.

Frequently asked questions

null
What percentage of Cidara Therapeutics is owned by insiders or institutions?
Currently 4.73% of Cidara Therapeutics shares are held by insiders and 51.858% by institutions. How many people work for Cidara Therapeutics?
Latest data suggests 69 work at Cidara Therapeutics. When does the fiscal year end for Cidara Therapeutics?
Cidara Therapeutics's fiscal year ends in December. Where is Cidara Therapeutics based?
Cidara Therapeutics's address is: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121 What is Cidara Therapeutics's ISIN number?
Cidara Therapeutics's international securities identification number is: US1717571079 What is Cidara Therapeutics's CUSIP number?
Cidara Therapeutics's Committee on Uniform Securities Identification Procedures number is: 171757107